Pfizer

Pfizer is a research-based biopharmaceutical company. The company is engaged in discovering, developing, manufacturing and distributing of healthcare products, including medicines and vaccines. The company manages its commercial operations through three businesses: Pfizer Biopharmaceuticals Group, which includes Oncology, Inflammation and Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine business units, as well as a hospital business unit; Upjohn, which includes the company's solid oral dose brands such as Lyrica, Lipitor, Norvasc, Celebrex, Viagra, and certain generic medicines; and Consumer Healthcare, which is an over-the-counter medicines business.
  • TickerPFE
  • ISINUS7170811035
  • ExchangeNew York Stock Exchange
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States
Dominic Rose ... (+2)
  • Dominic Rose
  • Naresh Chouhan
PFE PFIZER (Health Care)

COVID-19 - “Houston, We Have a Problem” (7 pgs)

An Israeli study published on Thursday showed that vaccine efficacy waned significantly against the Delta variant after ~6 months with efficacy down to just 16% for those vaccinated in January. Furthermore, hospitalisation rates also seemed to be higher in those vaccinated in January. Israel vaccinated its population the fastest so is best placed to conduct studies on vaccine durability. We assess the consequences of such a rapid loss of protection against the Delta variant which is becoming the dominant strain in most countries. We also show that recent UK studies that provided comfort regard...

PFE PFIZER (Health Care)

PFIZER increases its risk exposure and slightly lowers to Neutral

PFIZER (US), a company active in the Pharmaceuticals industry, now shows a lower overall rating. The independent financial analyst theScreener confirms the fundamental rating of 3 out of 4 stars. However, the market behaviour deterioration triggered a risk requalification, which can be thus described as moderately risky. theScreener believes that increased risk justifies the general evaluation downgrade to Neutral. As of the analysis date July 6, 2021, the closing price was USD 39.29 and its expected value was estimated at USD 39.21.

 PRESS RELEASE
PFE PFIZER (Health Care)

Pfizer Declares Third-Quarter 2021 Dividend

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a 39-cent third-quarter 2021 dividend on the company’s common stock, payable September 7, 2021, to holders of the Common Stock of record at the close of business on July 30, 2021. The third-quarter 2021 cash dividend will be the 331st consecutive quarterly dividend paid by Pfizer. About Pfizer: Breakthroughs That Change Patients’ Lives At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the ...

 PRESS RELEASE
PFE PFIZER (Health Care)

First Participant Dosed in Pfizer’s Pivotal Phase 3 TALAPRO-3 Combinat...

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today announced that the first participant has been dosed in TALAPRO-3, a global, randomized, double-blind, placebo-controlled Phase 3 clinical trial. The study will evaluate the efficacy and safety of talazoparib, an oral poly (ADP-ribose) polymerase (PARP) inhibitor, in combination with enzalutamide, an androgen receptor inhibitor, compared with placebo plus enzalutamide in men with DNA damage response (DDR)-deficient metastatic castration-sensitive prostate cancer (mCSPC). The first patient was dosed at a site in Glendale, California. “Th...

PFE PFIZER (Health Care)

Pfizer Inc. - April 2021 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Dominic Rose ... (+2)
  • Dominic Rose
  • Naresh Chouhan
PFE PFIZER (Health Care)

COVID-19 - “Houston, We Have a Problem” (7 pgs)

An Israeli study published on Thursday showed that vaccine efficacy waned significantly against the Delta variant after ~6 months with efficacy down to just 16% for those vaccinated in January. Furthermore, hospitalisation rates also seemed to be higher in those vaccinated in January. Israel vaccinated its population the fastest so is best placed to conduct studies on vaccine durability. We assess the consequences of such a rapid loss of protection against the Delta variant which is becoming the dominant strain in most countries. We also show that recent UK studies that provided comfort regard...

PFE PFIZER (Health Care)

PFIZER increases its risk exposure and slightly lowers to Neutral

PFIZER (US), a company active in the Pharmaceuticals industry, now shows a lower overall rating. The independent financial analyst theScreener confirms the fundamental rating of 3 out of 4 stars. However, the market behaviour deterioration triggered a risk requalification, which can be thus described as moderately risky. theScreener believes that increased risk justifies the general evaluation downgrade to Neutral. As of the analysis date July 6, 2021, the closing price was USD 39.29 and its expected value was estimated at USD 39.21.

 PRESS RELEASE
PFE PFIZER (Health Care)

Pfizer Declares Third-Quarter 2021 Dividend

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a 39-cent third-quarter 2021 dividend on the company’s common stock, payable September 7, 2021, to holders of the Common Stock of record at the close of business on July 30, 2021. The third-quarter 2021 cash dividend will be the 331st consecutive quarterly dividend paid by Pfizer. About Pfizer: Breakthroughs That Change Patients’ Lives At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the ...

 PRESS RELEASE
PFE PFIZER (Health Care)

First Participant Dosed in Pfizer’s Pivotal Phase 3 TALAPRO-3 Combinat...

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today announced that the first participant has been dosed in TALAPRO-3, a global, randomized, double-blind, placebo-controlled Phase 3 clinical trial. The study will evaluate the efficacy and safety of talazoparib, an oral poly (ADP-ribose) polymerase (PARP) inhibitor, in combination with enzalutamide, an androgen receptor inhibitor, compared with placebo plus enzalutamide in men with DNA damage response (DDR)-deficient metastatic castration-sensitive prostate cancer (mCSPC). The first patient was dosed at a site in Glendale, California. “Th...

PFE PFIZER (Health Care)

Pfizer Inc. - April 2021 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Dominic Rose ... (+2)
  • Dominic Rose
  • Naresh Chouhan
PFE PFIZER (Health Care)

COVID-19 - “Houston, We Have a Problem” (7 pgs)

An Israeli study published on Thursday showed that vaccine efficacy waned significantly against the Delta variant after ~6 months with efficacy down to just 16% for those vaccinated in January. Furthermore, hospitalisation rates also seemed to be higher in those vaccinated in January. Israel vaccinated its population the fastest so is best placed to conduct studies on vaccine durability. We assess the consequences of such a rapid loss of protection against the Delta variant which is becoming the dominant strain in most countries. We also show that recent UK studies that provided comfort regard...

PFE PFIZER (Health Care)

PFIZER increases its risk exposure and slightly lowers to Neutral

PFIZER (US), a company active in the Pharmaceuticals industry, now shows a lower overall rating. The independent financial analyst theScreener confirms the fundamental rating of 3 out of 4 stars. However, the market behaviour deterioration triggered a risk requalification, which can be thus described as moderately risky. theScreener believes that increased risk justifies the general evaluation downgrade to Neutral. As of the analysis date July 6, 2021, the closing price was USD 39.29 and its expected value was estimated at USD 39.21.

 PRESS RELEASE
PFE PFIZER (Health Care)

Pfizer Declares Third-Quarter 2021 Dividend

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a 39-cent third-quarter 2021 dividend on the company’s common stock, payable September 7, 2021, to holders of the Common Stock of record at the close of business on July 30, 2021. The third-quarter 2021 cash dividend will be the 331st consecutive quarterly dividend paid by Pfizer. About Pfizer: Breakthroughs That Change Patients’ Lives At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the ...

 PRESS RELEASE
PFE PFIZER (Health Care)

First Participant Dosed in Pfizer’s Pivotal Phase 3 TALAPRO-3 Combinat...

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today announced that the first participant has been dosed in TALAPRO-3, a global, randomized, double-blind, placebo-controlled Phase 3 clinical trial. The study will evaluate the efficacy and safety of talazoparib, an oral poly (ADP-ribose) polymerase (PARP) inhibitor, in combination with enzalutamide, an androgen receptor inhibitor, compared with placebo plus enzalutamide in men with DNA damage response (DDR)-deficient metastatic castration-sensitive prostate cancer (mCSPC). The first patient was dosed at a site in Glendale, California. “Th...

PFE PFIZER (Health Care)

Pfizer Inc. - April 2021 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Dominic Rose ... (+2)
  • Dominic Rose
  • Naresh Chouhan
PFE PFIZER (Health Care)

COVID-19 - “Houston, We Have a Problem” (7 pgs)

An Israeli study published on Thursday showed that vaccine efficacy waned significantly against the Delta variant after ~6 months with efficacy down to just 16% for those vaccinated in January. Furthermore, hospitalisation rates also seemed to be higher in those vaccinated in January. Israel vaccinated its population the fastest so is best placed to conduct studies on vaccine durability. We assess the consequences of such a rapid loss of protection against the Delta variant which is becoming the dominant strain in most countries. We also show that recent UK studies that provided comfort regard...

PFE PFIZER (Health Care)

PFIZER increases its risk exposure and slightly lowers to Neutral

PFIZER (US), a company active in the Pharmaceuticals industry, now shows a lower overall rating. The independent financial analyst theScreener confirms the fundamental rating of 3 out of 4 stars. However, the market behaviour deterioration triggered a risk requalification, which can be thus described as moderately risky. theScreener believes that increased risk justifies the general evaluation downgrade to Neutral. As of the analysis date July 6, 2021, the closing price was USD 39.29 and its expected value was estimated at USD 39.21.

 PRESS RELEASE
PFE PFIZER (Health Care)

Pfizer Declares Third-Quarter 2021 Dividend

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a 39-cent third-quarter 2021 dividend on the company’s common stock, payable September 7, 2021, to holders of the Common Stock of record at the close of business on July 30, 2021. The third-quarter 2021 cash dividend will be the 331st consecutive quarterly dividend paid by Pfizer. About Pfizer: Breakthroughs That Change Patients’ Lives At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the ...

 PRESS RELEASE
PFE PFIZER (Health Care)

First Participant Dosed in Pfizer’s Pivotal Phase 3 TALAPRO-3 Combinat...

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today announced that the first participant has been dosed in TALAPRO-3, a global, randomized, double-blind, placebo-controlled Phase 3 clinical trial. The study will evaluate the efficacy and safety of talazoparib, an oral poly (ADP-ribose) polymerase (PARP) inhibitor, in combination with enzalutamide, an androgen receptor inhibitor, compared with placebo plus enzalutamide in men with DNA damage response (DDR)-deficient metastatic castration-sensitive prostate cancer (mCSPC). The first patient was dosed at a site in Glendale, California. “Th...

PFE PFIZER (Health Care)

Pfizer Inc. - April 2021 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Dominic Rose ... (+2)
  • Dominic Rose
  • Naresh Chouhan
PFE PFIZER (Health Care)

COVID-19 - “Houston, We Have a Problem” (7 pgs)

An Israeli study published on Thursday showed that vaccine efficacy waned significantly against the Delta variant after ~6 months with efficacy down to just 16% for those vaccinated in January. Furthermore, hospitalisation rates also seemed to be higher in those vaccinated in January. Israel vaccinated its population the fastest so is best placed to conduct studies on vaccine durability. We assess the consequences of such a rapid loss of protection against the Delta variant which is becoming the dominant strain in most countries. We also show that recent UK studies that provided comfort regard...

PFE PFIZER (Health Care)

PFIZER increases its risk exposure and slightly lowers to Neutral

PFIZER (US), a company active in the Pharmaceuticals industry, now shows a lower overall rating. The independent financial analyst theScreener confirms the fundamental rating of 3 out of 4 stars. However, the market behaviour deterioration triggered a risk requalification, which can be thus described as moderately risky. theScreener believes that increased risk justifies the general evaluation downgrade to Neutral. As of the analysis date July 6, 2021, the closing price was USD 39.29 and its expected value was estimated at USD 39.21.

 PRESS RELEASE
PFE PFIZER (Health Care)

Pfizer Declares Third-Quarter 2021 Dividend

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a 39-cent third-quarter 2021 dividend on the company’s common stock, payable September 7, 2021, to holders of the Common Stock of record at the close of business on July 30, 2021. The third-quarter 2021 cash dividend will be the 331st consecutive quarterly dividend paid by Pfizer. About Pfizer: Breakthroughs That Change Patients’ Lives At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the ...

 PRESS RELEASE
PFE PFIZER (Health Care)

First Participant Dosed in Pfizer’s Pivotal Phase 3 TALAPRO-3 Combinat...

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today announced that the first participant has been dosed in TALAPRO-3, a global, randomized, double-blind, placebo-controlled Phase 3 clinical trial. The study will evaluate the efficacy and safety of talazoparib, an oral poly (ADP-ribose) polymerase (PARP) inhibitor, in combination with enzalutamide, an androgen receptor inhibitor, compared with placebo plus enzalutamide in men with DNA damage response (DDR)-deficient metastatic castration-sensitive prostate cancer (mCSPC). The first patient was dosed at a site in Glendale, California. “Th...

PFE PFIZER (Health Care)

Pfizer Inc. - April 2021 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Dominic Rose ... (+2)
  • Dominic Rose
  • Naresh Chouhan
PFE PFIZER (Health Care)

COVID-19 - “Houston, We Have a Problem” (7 pgs)

An Israeli study published on Thursday showed that vaccine efficacy waned significantly against the Delta variant after ~6 months with efficacy down to just 16% for those vaccinated in January. Furthermore, hospitalisation rates also seemed to be higher in those vaccinated in January. Israel vaccinated its population the fastest so is best placed to conduct studies on vaccine durability. We assess the consequences of such a rapid loss of protection against the Delta variant which is becoming the dominant strain in most countries. We also show that recent UK studies that provided comfort regard...

PFE PFIZER (Health Care)

PFIZER increases its risk exposure and slightly lowers to Neutral

PFIZER (US), a company active in the Pharmaceuticals industry, now shows a lower overall rating. The independent financial analyst theScreener confirms the fundamental rating of 3 out of 4 stars. However, the market behaviour deterioration triggered a risk requalification, which can be thus described as moderately risky. theScreener believes that increased risk justifies the general evaluation downgrade to Neutral. As of the analysis date July 6, 2021, the closing price was USD 39.29 and its expected value was estimated at USD 39.21.

 PRESS RELEASE
PFE PFIZER (Health Care)

Pfizer Declares Third-Quarter 2021 Dividend

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a 39-cent third-quarter 2021 dividend on the company’s common stock, payable September 7, 2021, to holders of the Common Stock of record at the close of business on July 30, 2021. The third-quarter 2021 cash dividend will be the 331st consecutive quarterly dividend paid by Pfizer. About Pfizer: Breakthroughs That Change Patients’ Lives At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the ...

 PRESS RELEASE
PFE PFIZER (Health Care)

First Participant Dosed in Pfizer’s Pivotal Phase 3 TALAPRO-3 Combinat...

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today announced that the first participant has been dosed in TALAPRO-3, a global, randomized, double-blind, placebo-controlled Phase 3 clinical trial. The study will evaluate the efficacy and safety of talazoparib, an oral poly (ADP-ribose) polymerase (PARP) inhibitor, in combination with enzalutamide, an androgen receptor inhibitor, compared with placebo plus enzalutamide in men with DNA damage response (DDR)-deficient metastatic castration-sensitive prostate cancer (mCSPC). The first patient was dosed at a site in Glendale, California. “Th...

PFE PFIZER (Health Care)

Pfizer Inc. - April 2021 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Dominic Rose ... (+2)
  • Dominic Rose
  • Naresh Chouhan
PFE PFIZER (Health Care)

COVID-19 - “Houston, We Have a Problem” (7 pgs)

An Israeli study published on Thursday showed that vaccine efficacy waned significantly against the Delta variant after ~6 months with efficacy down to just 16% for those vaccinated in January. Furthermore, hospitalisation rates also seemed to be higher in those vaccinated in January. Israel vaccinated its population the fastest so is best placed to conduct studies on vaccine durability. We assess the consequences of such a rapid loss of protection against the Delta variant which is becoming the dominant strain in most countries. We also show that recent UK studies that provided comfort regard...

PFE PFIZER (Health Care)

PFIZER increases its risk exposure and slightly lowers to Neutral

PFIZER (US), a company active in the Pharmaceuticals industry, now shows a lower overall rating. The independent financial analyst theScreener confirms the fundamental rating of 3 out of 4 stars. However, the market behaviour deterioration triggered a risk requalification, which can be thus described as moderately risky. theScreener believes that increased risk justifies the general evaluation downgrade to Neutral. As of the analysis date July 6, 2021, the closing price was USD 39.29 and its expected value was estimated at USD 39.21.

 PRESS RELEASE
PFE PFIZER (Health Care)

Pfizer Declares Third-Quarter 2021 Dividend

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a 39-cent third-quarter 2021 dividend on the company’s common stock, payable September 7, 2021, to holders of the Common Stock of record at the close of business on July 30, 2021. The third-quarter 2021 cash dividend will be the 331st consecutive quarterly dividend paid by Pfizer. About Pfizer: Breakthroughs That Change Patients’ Lives At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the ...

 PRESS RELEASE
PFE PFIZER (Health Care)

First Participant Dosed in Pfizer’s Pivotal Phase 3 TALAPRO-3 Combinat...

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today announced that the first participant has been dosed in TALAPRO-3, a global, randomized, double-blind, placebo-controlled Phase 3 clinical trial. The study will evaluate the efficacy and safety of talazoparib, an oral poly (ADP-ribose) polymerase (PARP) inhibitor, in combination with enzalutamide, an androgen receptor inhibitor, compared with placebo plus enzalutamide in men with DNA damage response (DDR)-deficient metastatic castration-sensitive prostate cancer (mCSPC). The first patient was dosed at a site in Glendale, California. “Th...

PFE PFIZER (Health Care)

Pfizer Inc. - April 2021 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch